STAT+: ‘What can we do?’: Pharma lobbyists face their biggest test in a decade, as Democrats barrel toward a vote on drug pricing

Pharma’s lobbyists are staring down their biggest test yet, as Democrats barrel toward a vote on drug pricing reform.

WASHINGTON — The pharmaceutical industry, notorious for its deep pockets and aggressive lobbying tactics, has a nearly spotless record dominating policy fights. Now, the sector is staring down its biggest test in at least a decade.

Democrats are closer than ever before to finally achieving a goal they’ve been pursuing for nearly two decades — allowing Medicare to negotiate prescription drug prices. Skeptical lawmakers seem to be on board; the bill text is already under review by the Senate’s rules referee. Congressional leadership and the White House have come up with a plan to barrel toward a vote that could come as soon as next week.

Continue to STAT+ to read the full story…